Literature DB >> 7249785

Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers.

T Bergan, P E Bjerke, O Fausa.   

Abstract

Tablets of 500 mg metronidazole were given to 24 patients with intestinal diseases and to 10 healthy volunteers. The diagnoses included coeliac disease, ulcerative colitis, jejunoileal shunt, ileostomy, and Crohn's disease. Both normal subjects and patients exhibited considerable variation in serum metronidazole concentrations. This applied particularly to the patients who had somewhat slower absorption and later occurrence of serum peaks than did the normal subjects. No major deviation occurred within any of the diagnostic groups. All but the ileostomy patients exhibited a lag before apparent absorption. The individual peaks occurred after 1.5-2.0 h and was 12.7 +/- 2.1 microgram/ml in all disease groups, except the ileostomy patients who exhibited a mean of 16.2 microgram/ml. In the healthy subjects, the mean peak was 12.1 +/- 4.6 microgram/ml. A major finding was the observation that the patients as a group had a higher total area under the serum curves (AUC) than the volunteers. The AUC of normal volunteers was 108.1 microgram . h . ml-1 compared to 260.5 microgram . h. ml-1 in the patients with ileostomy and 147.6 microgram . h . ml-1 for the others. The higher AUC values in the ileostomy group were associated with longer serum half-life values. The serum half-life was 8.3 in the normals, 11.9 with ileostomy and 7.2 h in the remainder. The normal individuals and the patients with ulcerative colitis had higher rates of absorption, those with coeliac disease or ileostomy lower absorption rates than was found elsewhere. The relative volume of distribution (the distribution coefficient) was the same in the healthy individuals as in each patients group, except for the ileostomy patients. The total body clearance was 1.94 liters/h in ileostomy, 3.68 liters/h in the other patients, and 5.43 liters/h in the normal subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249785     DOI: 10.1159/000237985

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  Systematic review of drug bioavailability following gastrointestinal surgery.

Authors:  Manuela Moreno Santamaría; José Javier Arenas Villafranca; Jimena Abilés; Alberto Fernández López; Lucia Visiedo Rodas; Begoña Tortajada Goitia; Pilar Utrilla Navarro
Journal:  Eur J Clin Pharmacol       Date:  2018-08-22       Impact factor: 2.953

2.  Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.

Authors:  J L Shaffer; A Kershaw; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

4.  Gastric aspiration by nasal intubation: an additional route of elimination for metronidazole.

Authors:  B Diquet; J F Thiercelin; P Simon; F Ghesquière; P Viars
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 5.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 6.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.

Authors:  P O Gubbins; K E Bertch
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

9.  Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice.

Authors:  Lenka Jourova; Stefan Satka; Veronika Frybortova; Iveta Zapletalova; Pavel Anzenbacher; Eva Anzenbacherova; Petra Petr Hermanova; Barbora Drabonova; Dagmar Srutkova; Hana Kozakova; Tomas Hudcovic
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

10.  Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review.

Authors:  Wallace Bok-Thoe Hong; Wee Kiat Tan; Lawrence Siu-Chun Law; David Eng-Hui Ong; Elaine Ah-Gi Lo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-01       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.